DE60202877D1 - TARGETED ANTIBODY PROCEDURE - Google Patents
TARGETED ANTIBODY PROCEDUREInfo
- Publication number
- DE60202877D1 DE60202877D1 DE60202877T DE60202877T DE60202877D1 DE 60202877 D1 DE60202877 D1 DE 60202877D1 DE 60202877 T DE60202877 T DE 60202877T DE 60202877 T DE60202877 T DE 60202877T DE 60202877 D1 DE60202877 D1 DE 60202877D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- targeted antibody
- vaccine
- antibody procedure
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6818—Sequencing of polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention concerns methods for identifying candidate sequences for antibody specific against an antigen produced by a micro-organism during an infection or against a vaccine, methods of manufacture of medicaments, and methods of treatment of patients using same. Also provided is a method for determining the efficacy of a vaccine, together with methods of vaccinating a patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0130267.8A GB0130267D0 (en) | 2001-12-19 | 2001-12-19 | Focussed antibody technology |
GB0130267 | 2001-12-19 | ||
PCT/GB2002/005690 WO2003052416A2 (en) | 2001-12-19 | 2002-12-16 | Focussed antibody technology |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60202877D1 true DE60202877D1 (en) | 2005-03-10 |
DE60202877T2 DE60202877T2 (en) | 2006-04-13 |
Family
ID=9927861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60202877T Expired - Lifetime DE60202877T2 (en) | 2001-12-19 | 2002-12-16 | TARGETED ANTIBODY PROCEDURE |
Country Status (10)
Country | Link |
---|---|
US (1) | US20060233812A1 (en) |
EP (1) | EP1415002B1 (en) |
AT (1) | ATE288502T1 (en) |
AU (1) | AU2002352394A1 (en) |
CA (1) | CA2471570A1 (en) |
DE (1) | DE60202877T2 (en) |
ES (1) | ES2236605T3 (en) |
GB (1) | GB0130267D0 (en) |
PT (1) | PT1415002E (en) |
WO (1) | WO2003052416A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
GB0414886D0 (en) | 2004-07-02 | 2004-08-04 | Neutec Pharma Plc | Treatment of bacterial infections |
EP2088432A1 (en) * | 2008-02-11 | 2009-08-12 | MorphoSys AG | Methods for identification of an antibody or a target |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
GB2477439B (en) | 2008-11-07 | 2012-02-15 | Sequenta Inc | Methods for correlating clonotypes with a disease in a patient |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
ES2568509T3 (en) | 2009-01-15 | 2016-04-29 | Adaptive Biotechnologies Corporation | Adaptive immunity profiling and methods for the generation of monoclonal antibodies |
US9079942B2 (en) * | 2009-02-09 | 2015-07-14 | Epitomics, Inc. | CDR-anchored amplification method |
JP5804521B2 (en) | 2009-05-29 | 2015-11-04 | モルフォシス・アー・ゲー | Collection and its usage |
US20100317539A1 (en) * | 2009-06-12 | 2010-12-16 | Guo-Liang Yu | Library of Engineered-Antibody Producing Cells |
RU2014144463A (en) | 2009-06-25 | 2015-06-20 | Фред Хатчинсон Кансэр Рисёч Сентер | METHOD FOR ADAPTIVE IMMUNITY MEASUREMENT |
US8293483B2 (en) | 2009-09-11 | 2012-10-23 | Epitomics, Inc. | Method for identifying lineage-related antibodies |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
SI3095871T1 (en) | 2010-02-08 | 2019-06-28 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
WO2011146514A2 (en) * | 2010-05-17 | 2011-11-24 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
CA2816558C (en) | 2010-11-19 | 2020-12-29 | Morphosys Ag | A collection and methods for its use |
HUE037095T2 (en) | 2011-03-09 | 2018-08-28 | Cell Signaling Technology Inc | Methods and reagents for creating monoclonal antibodies |
RS61946B1 (en) | 2011-08-05 | 2021-07-30 | Regeneron Pharma | Humanized universal light chain mice |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
CA2791109C (en) * | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
US9279159B2 (en) | 2011-10-21 | 2016-03-08 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
WO2013078455A2 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Proteomic identification of antibodies |
ES2683037T3 (en) | 2011-12-09 | 2018-09-24 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignant tumors and detection of minimal residual disease |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
DK2823060T3 (en) | 2012-03-05 | 2018-05-28 | Adaptive Biotechnologies Corp | Determination of associated immune receptor chains from frequency-matched subunits |
ES2743399T3 (en) | 2012-04-20 | 2020-02-19 | Merus Nv | Methods and means for the production of Ig-like heterodimeric molecules |
US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
US9708654B2 (en) | 2012-06-15 | 2017-07-18 | Board Of Regents, The University Of Texas System | High throughput sequencing of multiple transcripts |
CN105189779B (en) | 2012-10-01 | 2018-05-11 | 适应生物技术公司 | The immunocompetence carried out by adaptive immunity receptor diversity and Clonal characterization is assessed |
WO2015160439A2 (en) | 2014-04-17 | 2015-10-22 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
AU2015227054A1 (en) | 2014-03-05 | 2016-09-22 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
AU2015339191A1 (en) | 2014-10-29 | 2017-05-18 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
WO2016086029A1 (en) | 2014-11-25 | 2016-06-02 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
AU2016222788B2 (en) | 2015-02-24 | 2022-03-31 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US10513733B2 (en) | 2015-03-23 | 2019-12-24 | Board Of Regents, The University Of Texas System | High throughout sequencing of paired VH and VL transcripts from B cells secreting antigen-specific antibodies |
EP3277294B1 (en) | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
WO2019084538A1 (en) | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | Tumor specific antibodies and t-cell receptors and methods of identifying the same |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007713A1 (en) * | 1988-12-29 | 1990-07-12 | Cytogen Corporation | Molecular recognition units |
US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
DE19739685A1 (en) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoclonal antibodies for the therapy and prophylaxis of diseases caused by Clostridium difficile |
DE60124313T2 (en) * | 2001-01-15 | 2007-05-31 | Keryos S.P.A. | DNA VACCINES OF HYPERVARIABLES VH-CDR3 IDIOTYPIC DETERMINANTS |
GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
-
2001
- 2001-12-19 GB GBGB0130267.8A patent/GB0130267D0/en not_active Ceased
-
2002
- 2002-12-16 WO PCT/GB2002/005690 patent/WO2003052416A2/en not_active Application Discontinuation
- 2002-12-16 PT PT02788114T patent/PT1415002E/en unknown
- 2002-12-16 US US10/499,104 patent/US20060233812A1/en not_active Abandoned
- 2002-12-16 EP EP02788114A patent/EP1415002B1/en not_active Expired - Lifetime
- 2002-12-16 ES ES02788114T patent/ES2236605T3/en not_active Expired - Lifetime
- 2002-12-16 DE DE60202877T patent/DE60202877T2/en not_active Expired - Lifetime
- 2002-12-16 CA CA002471570A patent/CA2471570A1/en not_active Abandoned
- 2002-12-16 AT AT02788114T patent/ATE288502T1/en active
- 2002-12-16 AU AU2002352394A patent/AU2002352394A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1415002A2 (en) | 2004-05-06 |
ES2236605T3 (en) | 2005-07-16 |
ATE288502T1 (en) | 2005-02-15 |
PT1415002E (en) | 2005-05-31 |
DE60202877T2 (en) | 2006-04-13 |
EP1415002B1 (en) | 2005-02-02 |
WO2003052416A2 (en) | 2003-06-26 |
CA2471570A1 (en) | 2003-06-26 |
AU2002352394A1 (en) | 2003-06-30 |
WO2003052416A3 (en) | 2003-10-16 |
GB0130267D0 (en) | 2002-02-06 |
US20060233812A1 (en) | 2006-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60202877D1 (en) | TARGETED ANTIBODY PROCEDURE | |
HUP0400313A2 (en) | A novel engineered superantigen for human therapy | |
CY1108765T1 (en) | ANTI-ErbB2 antibody treatment | |
CY1113243T1 (en) | METHODS OF TREATMENT USING CTLA-4 | |
DE60228758D1 (en) | IMMUNIZATION AGAINST CHLAMYDIA TRACHEOMATIS | |
TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
CY1110783T1 (en) | Monoclonal Antibodies Against Growth Factor | |
CY1105389T1 (en) | HPV-E7 AS A TREATMENT AGAINST HUMAN PAMOVAL VIRUS | |
TW200514593A (en) | Method and device for enhancing transdermal agent flux | |
WO2003039462A3 (en) | B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies | |
ATE521361T1 (en) | METHOD FOR TREATING CERVICAL CANCER | |
ID30223A (en) | ANTIBODIC USE FOR VACCINATION AGAINST CANCER | |
HUP0301634A2 (en) | Temperature-sensitive live vaccine for mycoplasma hyopneumoniae | |
DE60218473D1 (en) | METHOD FOR PRODUCING POLYVALENT BACTERIOPHAGE PREPARATIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
ATE381942T1 (en) | AGENTS FOR THE TREATMENT OF LEISHMANIA INFECTIONS | |
WO2002072013A3 (en) | Method of treating malignancies through induction of blood immune responses | |
EP1667634A4 (en) | Anthrax vaccine | |
DE60233936D1 (en) | Therapeutic connections for tolerance induction | |
DK1146889T3 (en) | Identification of Specific Differentially Expressed Mycobacterial Antigens and Medical Use of Mycobacterium Proteins Rv0068 and Rv3407 | |
BR0318688A (en) | polypeptide for the diagnosis and therapy of leishmania | |
ATE297745T1 (en) | CHEMICAL MODIFICATION OF MAMMAL URINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8365 | Fully valid after opposition proceedings |